{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:46:56Z","timestamp":1792432016721,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00432-022-04177-w","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T10:02:41Z","timestamp":1658311361000},"page":"3557-3566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["PD-1 inhibitors plus chemotherapy in EGFR\/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR\/ALK-TKIs therapy"],"prefix":"10.1007","volume":"148","author":[{"given":"Yixiang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingsheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"issue":"11","key":"4177_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1200\/JOP.19.00357","volume":"15","author":"V Ernani","year":"2019","unstructured":"Ernani V, Stinchcombe TE (2019) Management of brain metastases in non-small-cell lung cancer. J Oncol Pract 15(11):563\u2013570. https:\/\/doi.org\/10.1200\/JOP.19.00357 (Erratum in: JCO Oncol Pract 2020 Mar;16(3):149.\u00a0doi: 10.1200\/JOP.20.00042)","journal-title":"J Oncol Pract"},{"issue":"11","key":"4177_CR2","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, Mezquita L, Texier M et al (2018) Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 4(11):1543\u20131552. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3676","journal-title":"JAMA Oncol"},{"key":"4177_CR3","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Shaw AT, Sequist LV et al (2016) EGFR mutations and alk rearrangements are associated with low response rates to pd-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22:4585\u20134593. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3101","journal-title":"Clin Cancer Res"},{"key":"4177_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","volume":"4","author":"MC Garassino","year":"2018","unstructured":"Garassino MC, Cho BC, Kim JH et al (2018) Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol 4:521\u2013536. https:\/\/doi.org\/10.1016\/S1470-2045(18)30144-X","journal-title":"Lancet Oncol"},{"key":"4177_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"5","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Schalper KA, Gettinger SN et al (2020) Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol 5:655\u2013663. https:\/\/doi.org\/10.1016\/S1470-2045(20)30111-X","journal-title":"Lancet Oncol"},{"issue":"3","key":"4177_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/annonc\/mdx820","volume":"29","author":"G Goss","year":"2018","unstructured":"Goss G, Tsai CM, Shepherd FA et al (2018) CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol 29(3):687\u2013693. https:\/\/doi.org\/10.1093\/annonc\/mdx820","journal-title":"Ann Oncol"},{"issue":"6","key":"4177_CR7","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.21037\/tlcr-20-941","volume":"10","author":"G Guaitoli","year":"2021","unstructured":"Guaitoli G, Tiseo M, Di Maio M et al (2021) Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res 10(6):2890\u20132916. https:\/\/doi.org\/10.21037\/tlcr-20-941","journal-title":"Transl Lung Cancer Res"},{"issue":"8","key":"4177_CR8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","volume":"21","author":"R Kotecha","year":"2019","unstructured":"Kotecha R, Kim JM, Miller JA et al (2019) The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro-oncol (Charlottesv Va.) 21(8):1060\u20131068. https:\/\/doi.org\/10.1093\/neuonc\/noz046","journal-title":"Neuro-oncol (Charlottesv Va.)"},{"issue":"5","key":"4177_CR9","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/1759-7714.13057","volume":"10","author":"CS Kuo","year":"2019","unstructured":"Kuo CS, Wang CC, Huang YC et al (2019) Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. Thorac Cancer 10(5):1158\u20131166. https:\/\/doi.org\/10.1111\/1759-7714.13057","journal-title":"Thorac Cancer"},{"issue":"7","key":"4177_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jtho.2021.03.016","volume":"16","author":"L Liu","year":"2021","unstructured":"Liu L, Bai H, Wang C et al (2021) Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis. J Thorac Oncol 16(7):1099\u20131117. https:\/\/doi.org\/10.1016\/j.jtho.2021.03.016","journal-title":"J Thorac Oncol"},{"key":"4177_CR11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A et al (2019) Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 30:1321\u20131328. https:\/\/doi.org\/10.1093\/annonc\/mdz167","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"4177_CR12","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.21037\/tlcr.2019.05.15","volume":"8","author":"M Nishino","year":"2019","unstructured":"Nishino M, Soejima K, Mitsudomi T (2019) Brain metastases in oncogene-driven non-small cell lung cancer. Transl Lung Cancer Res 8(Suppl 3):S298\u2013S307. https:\/\/doi.org\/10.21037\/tlcr.2019.05.15","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"4177_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382(1):41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"issue":"5","key":"4177_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","volume":"7","author":"M Reck","year":"2019","unstructured":"Reck M, Mok TSK, Nishio M et al (2019) Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 7(5):387\u2013401. https:\/\/doi.org\/10.1016\/S2213-2600(19)30084-0 (Epub 2019 Mar 25)","journal-title":"Lancet Respir Med"},{"key":"4177_CR15","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","volume":"36","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC et al (2018) CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 36:3290\u20133297. https:\/\/doi.org\/10.1200\/JCO.2018.78.3118","journal-title":"J Clin Oncol."},{"issue":"5","key":"4177_CR16","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/COC.0000000000000538","volume":"42","author":"Y Song","year":"2019","unstructured":"Song Y, Wu YL, Cao LJ et al (2019) Efficacy and safety of Gefitinib as third-line treatment in NSCLC patients with activating EGFR mutations treated with first-line Gefitinib followed by second-line chemotherapy: a single-arm, prospective, multicenter phase II study (RE-CHALLENGE, CTONG1304). Am J Clin Oncol 42(5):432\u2013439. https:\/\/doi.org\/10.1097\/COC.0000000000000538","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"4177_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"issue":"7","key":"4177_CR18","doi-asserted-by":"publisher","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","volume":"115","author":"D Taggart","year":"2018","unstructured":"Taggart D, Andreou T, Scott KJ et al (2018) Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking. Proc Natl Acad Sci USA 115(7):E1540\u2013E1549. https:\/\/doi.org\/10.1073\/pnas.1714089115 (Epub 2018 Jan 31)","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"4177_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1513\/pats.201107-042ST","volume":"8","author":"WD Travis","year":"2011","unstructured":"Travis WD, Brambilla E, Noguchi M et al (2011) International association for the study of lung cancer\/American thoracic society\/european respiratory society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 8(5):381\u20135. https:\/\/doi.org\/10.1513\/pats.201107-042ST","journal-title":"Proc Am Thorac Soc"},{"key":"4177_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/B978-0-12-811161-1.00011-6","volume":"149","author":"VA Venur","year":"2018","unstructured":"Venur VA, Karivedu V, Ahluwalia MS (2018) Systemic therapy for brain metastases. Handb Clin Neurol 149:137\u2013153. https:\/\/doi.org\/10.1016\/B978-0-12-811161-1.00011-6","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"4177_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S1556-0864(18)30417-9","volume":"13","author":"JCH Yang","year":"2018","unstructured":"Yang JCH, Wu YL, Hirsh V et al (2018) Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, 7. J Thorac Oncol 13(4):84\u201385. https:\/\/doi.org\/10.1016\/S1556-0864(18)30417-9","journal-title":"J Thorac Oncol"},{"key":"4177_CR22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.21037\/jtd.2019.03.76","volume":"4","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Guo H, Lu Y et al (2019) Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis. J Thorac Dis 4:1397\u20131409. https:\/\/doi.org\/10.21037\/jtd.2019.03.76","journal-title":"J Thorac Dis"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04177-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T07:13:03Z","timestamp":1666336383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04177-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4177"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04177-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no financial disclosures or conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (Approval No: 20\/361\u20132145).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed and approved the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}